

# Open trial for patients with relapsed or refractory T-cell lymphoma

A Phase I study of carfilzomib for the treatment of T-cell lymphoma

## Objective:

- To assess the safety and preliminary efficacy of single agent carfilzomib in patients with relapsed and refractory peripheral T-cell lymphoma (PTCL), including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), NK/T-cell lymphoma (NK/TCL) and PTCL-unspecified (PTCL-U).

## Key eligibility criteria:

- Age of  $\geq 19$  years with Karnofsky Performance Status  $\geq 70$ .
- Well controlled hypertension or diabetes.
- No prior malignancies within the past two years with exception of adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix or breast, or prostate cancer of Gleason grade 6 or less with stable PSA levels.
- No active infection.
- No impaired cardiac function.
- No significant peripheral neuropathy.



## Procedures:

- Patients come to MD Anderson every cycle/28 days for physical exams and carfilzomib infusion.
- Routine labs every cycle/28 days.
- CT at time of study entry and every 3 cycles of therapy

## Potential Benefits for Patients:

- Carfilzomib is proteasome inhibitor that was recently FDA approved for the treatment of relapsed multiple myeloma.
- This trial uses the approved dosing schema and evaluates this therapy in patients with relapsed T-cell lymphoma.
- We hypothesize this therapy might have improved benefit as compared to bortezomib historical response rates and also potentially less risk of peripheral neuropathy.

**Protocol # 2011-0183**

**Principal investigator: Michelle Fanale, M.D.**

Schedule an appointment by contacting Rommel Quiambao in the Lymphoma Clinic at 713-745-5634 or make referral online at <https://my.mdanderson.org>

For more information about the study, please email Michelle Fanale, M.D., at [mfanale@mdanderson.org](mailto:mfanale@mdanderson.org) or Jessie Tian, R.N. at [ttian@mdanderson.org](mailto:ttian@mdanderson.org)

For information on related articles or references for this study, visit <http://physicianrelations.org> or <http://clinicaltrials.gov/ct2/show/NCT01309789>

THE UNIVERSITY OF TEXAS

**MD Anderson  
Cancer Center**

Making Cancer History®